يعرض 1 - 20 نتائج من 48 نتيجة بحث عن '"Hanes, V"', وقت الاستعلام: 0.65s تنقيح النتائج
  1. 1
    Academic Journal
  2. 2
  3. 3
    Academic Journal
  4. 4
    Academic Journal
  5. 5
    Academic Journal
  6. 6
    Academic Journal
  7. 7
    Academic Journal

    المساهمون: Kulasekararaj, A, Lanza, F, Arvanitakis, A, Langemeijer, SMC, Chonat, S, Chow, V, Pan, J, Saportas, Y, Hanes, V, Henary, H

    وصف الملف: ELETTRONICO

    Relation: info:eu-repo/semantics/altIdentifier/wos/WOS:000893230301324; volume:140; issue:Supplement 1; firstpage:8660; lastpage:8662; numberofpages:3; journal:BLOOD; https://hdl.handle.net/11585/924185

  8. 8
    Academic Journal
  9. 9
    Academic Journal
  10. 10
    Academic Journal
  11. 11
    Conference

    المساهمون: Thoraxklinik at Heidelberg University Hospital, Heidelberg, Germany

    Relation: https://dx.doi.org/10.1200/JCO.2019.37.15_suppl.e20708; Thomas M, Thatcher N, Goldschmidt J, Ohe Y, McBride H, Hanes V. Totality of evidence in development of the bevacizumab biosimilar ABP 215: central and investigator evaluation of efficacy from the MAPLE study. J Clin Oncol. 2019;37(15).; http://hdl.handle.net/10541/622469; Journal of Clinical Oncology

  12. 12
    Conference

    المصدر: Senologie - Zeitschrift für Mammadiagnostik und -therapie ; 39. Jahrestagung der Deutschen Gesellschaft für Senologie ; ISSN 1611-647X

  13. 13
    Conference
  14. 14
    Academic Journal
  15. 15
    Academic Journal
  16. 16
    Conference
  17. 17
    Academic Journal

    المساهمون: Internistische Onkologie der Thoraxtumoren, Thoraxklinik im Universitatsklinikum Heidelberg, Translational Lung Research Center, Heidelberg, Germany

    Relation: https://dx.doi.org/10.2217/imt-2019-0125; Thomas M, Thatcher N, Goldschmidt J, Ohe Y, McBride HJ, Hanes V. Totality of evidence in the development of ABP 215, an approved bevacizumab biosimilar. Immunotherapy. 2019;11(15):1337-51.; http://hdl.handle.net/10541/622413; Immunotherapy

  18. 18
    Academic Journal

    المساهمون: The Christie Hospital, Manchester, United Kingdom

    Relation: https://dx.doi.org/10.1158/1078-0432.CCR-18-2702; Thatcher N, Goldschmidt JH, Thomas M, Schenker M, Pan Z, Paz-Ares Rodriguez L, et al. Efficacy and safety of the biosimilar ABP 215 compared with bevacizumab in patients with advanced nonsquamous non-small cell lung cancer (MAPLE): a randomized, double-blind, phase III study. Clin Cancer Res. 2019; 25(7):2088-95.; http://hdl.handle.net/10541/621831; Clinical Cancer Research

  19. 19
    Academic Journal

    المؤلفون: Thill, M, Thatcher, Nick, Hanes, V, Lyman, H

    المساهمون: Department of Medical Oncology, Gustave Roussy, Villejuif, France

    Relation: https://dx.doi.org/10.2217/fon-2018-0728; Thill M, Thatcher N, Hanes V, Lyman G. Biosimilars: what the oncologist should know. Future Oncol. 2019.; http://hdl.handle.net/10541/621701; Future Oncology

  20. 20
    Academic Journal